NovaBone Products was established in 2002 with a focus on developing bone graft substitutes based on advancements in biomedical engineering that would meet the specialized needs of orthopedic and dental surgeons. Since its inception, our company has developed numerous formulations and delivery systems of its patented, bioactive technology platform that results in accelerated bone growth. In total, our exclusively formulated bone graft substitute has been used for the repair of osseous defects throughout the skeletal system for over a decade and used in over a million clinical applications with unparalleled success validating the safety and efficacy of NovaBone's technology. NovaBone® was the first bioactive synthetic bone graft offered to the orthopedic community; the unique properties of the product formulation gave rise to the need to scientifically define its bone-forming process, and in 2005, the FDA authorized the term “osteostimulation,” as a way to describe how our products signal genetic pathways to accelerate natural regeneration of bone.